CTOR Company Profile and Key Details

Citius Oncology, Inc. has 78.37 million shares outstanding. The public float is 16.37 million shares, elevated short interest at 2.46% of float. This equals 303.36 thousand shares. The short ratio is 0.84 days. Institutional investors hold 5.71% of the float. Insiders own 86.83%.

CTOR has shown mixed momentum, losing -1.87% over the past week and -38.24% over the past quarter, though year-to-date performance is up 5.0%. Short-term trend indicators are mixed aligned (SMA20 -3.88%, SMA50 -3.19%, SMA200 -32.83%). The stock’s 14-day RSI is 43.99 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.39% below its high and over 97.97% above its low. Average 10-day trading volume of 188.93 thousand shares is below the 3-month average of 213.17 thousand, indicating normal recent market interest.

Citius Oncology, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is -309.67%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 934.48% upside. The low target suggests 934.48% downside. The mean target is $6.00. This offers 934.48% upside. Citius Oncology, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended December 23, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in December 27, 2024.

Citius Oncology, Inc. (NASDAQ:CTOR) closed at $0.58 USD, losing -$0.04 (-6.83%) from the previous close of $0.63. The stock is currently trading near its 52-week low $0.58 and $6.19. With a market capitalization of about $51.43 million, Citius Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.04). Key stats such as the average daily volume over the past year has been around 298.58 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Citius Oncology, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Citius Oncology, Inc. trades at a P/E ratio of -2.21, slightly below the S&P 500 average, with a price-to-sales ratio of 13.38 and a price-to-book ratio of 0.89 suggesting the stock is closer to book value. The P/FCF stands at -4.09, also below market averages.

Citius Oncology, Inc. (NASDAQ:CTOR) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Oncology, Inc. trading at a premium to the broader market with a P/E of -2.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.50, suggesting 672.4% upside. Our AI forecast model points to short-term weakness (-69.1% over two weeks), a medium-term fall (-46.79% over three months), and a longer-term loss (-84.55% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Citius Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -69.1%, with price expected at $0.18 by April 07, 2026, within a range of $0.12 to $0.24 3-Month Outlook: Projected fall of -46.79%, reaching $0.31 by June 22, 2026, with a range of $0.12 to $0.36. 1-Year Outlook: Projected loss of -84.55%, with price at $0.09 by March 24, 2027, within a range of $0.00 to $0.00.